ADx NeuroSciences teams up with Japanese partner

October 12, 2016 News Quality by Design - Business & Communications

ADx NeuroSciences has signed a collaborative R&D agreement with the Japanese Nipro Corporation. The companies will jointly develop next-generation in vitro diagnostics for Alzheimer’s disease. The agreement was officially signed during the Belgian Royal State Visit to Japan.

Japan has the oldest population in the world and the country counts more than 4.6 million Alzheimer patients. Japanese pharmaceutical companies have Alzheimer’s drug development high on their priority list and invest heavily in solutions for the disease. Nipro has a long standing experience in the development and commercialization of diagnostics and treatments of Alzheimer’s. Together with ADx, the company will now look into the development of Point Of Care diagnostic devices.

Koen Dewaele, CEO ADx NeuroSciences: “This collaboration is yet another confirmation of our successful business model. ADx is the global number 1 provider of high quality antibodies for diagnostics of neurodegenerative diseases like Alzheimer’s and Parkinson’s.”

Yoshida Hiroshi, Director R&D development Nipro: “We know the people at ADx have a lot of expertise in the field of Alzheimer’s. Their valuable antibodies help us to develop state-of-the-art Alzheimer’s diagnostics.”

Read the full press release here.

Avatar photo
Quality by Design - Business & Communications

Quality by Design (QbD) - Business & Communications is a team of expert strategists, scientists, communicators, and creatives. Whether you're a part of an innovative startup or an established player, our unique approach will ensure that your company has the best chance of being seen and understood by your target audience: prospects, clients, investors, partners, and more. We don’t just consult; we also help you implement. We share articles on BioVox providing insight into new and established players in the Benelux Life Science ecosystem, from innovations and research breakthroughs through to finance and industry trends.

All posts

Subscribe to the BioVox newsletter